Literature DB >> 29155799

Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3.

O P Almeida1,2,3, G J Hankey4,5, B B Yeap4,6, S A Paul Chubb4,6, J Gollege7,8, L Flicker4,9,10.   

Abstract

Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5%) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6%) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23% (95% confidence interval=5-37%). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29155799     DOI: 10.1038/mp.2017.152

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  6 in total

Review 1.  Physical Activity and Alzheimer's Disease: A Narrative Review.

Authors:  Piotr Gronek; Stefan Balko; Joanna Gronek; Adam Zajac; Adam Maszczyk; Roman Celka; Agnieszka Doberska; Wojciech Czarny; Robert Podstawski; Cain C T Clark; Fang Yu
Journal:  Aging Dis       Date:  2019-12-01       Impact factor: 6.745

2.  Inhibition of miR-19a-3p decreases cerebral ischemia/reperfusion injury by targeting IGFBP3 in vivo and in vitro.

Authors:  Zhaohui Chai; Jiangbiao Gong; Peidong Zheng; Jiesheng Zheng
Journal:  Biol Res       Date:  2020-04-20       Impact factor: 5.612

3.  Blood-based biomarkers in hypothalamic-pituitary axes for the risk of dementia or cognitive decline: a systematic review and meta-analysis.

Authors:  Yi-Jun Ge; Wei Xu; Chen-Chen Tan; Lan Tan
Journal:  Aging (Albany NY)       Date:  2020-10-26       Impact factor: 5.682

4.  Circulating Insulin-Like Growth Factor I is Involved in the Effect of High Fat Diet on Peripheral Amyloid β Clearance.

Authors:  Raquel Herrero-Labrador; Angel Trueba-Saiz; Laura Martinez-Rachadell; Mᵃ Estrella Fernandez de Sevilla; Jonathan A Zegarra-Valdivia; Jaime Pignatelli; Sonia Diaz-Pacheco; Ana M Fernandez; Ignacio Torres Aleman
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

5.  Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume.

Authors:  Antoine Salzmann; Sarah-Naomi James; Dylan M Williams; Marcus Richards; Dorina Cadar; Jonathan M Schott; William Coath; Carole H Sudre; Nishi Chaturvedi; Victoria Garfield
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

6.  Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial).

Authors:  Danni Li; Michelle M Mielke; W Robert Bell; Cavan Reilly; Lin Zhang; Feng Vankee Lin; Fang Yu
Journal:  Trials       Date:  2020-01-06       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.